Latest Articles

Publication Date
Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis.

[This corrects the article DOI: 10.3389/fimmu.2021.641206.].

Published: Nov. 24, 2025, midnight
Lactate-mediated immune suppression and MDSC expansion in endometriosis: Mechanisms and nanoparticle-targeted therapies.

Endometriosis, a chronic gynecological disorder characterized by the ectopic growth of endometrial-like tissue, is associated with severe pelvic pain, infertility, and profound immune dysregulation. Despite advances in hormonal therapy and …

Published: Nov. 1, 2025, midnight
mTOR inhibitors as potential therapeutics for endometriosis: A narrative review.

Mammalian target of rapamycin (mTOR) inhibitors have been used clinically as anticancer and immunosuppressive agents for over 20 years, demonstrating their safety after long-term administration. These inhibitors exhibit various effects, …

Published: Nov. 23, 2024, midnight
Cryptotanshinone alleviates immunosuppression in endometriosis by targeting MDSCs through JAK2/STAT3 pathway.

Endometriosis (EMS), a well-recognized chronic inflammatory disorder, characterized by significant immune dysregulation, in which myeloid-derived suppressor cells (MDSCs) are essential for facilitating immunosuppression and driving to disease progression. Cryptotanshinone (CTS) …

Published: Nov. 14, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!